FDA Issues Final Guidance for ANDA Amendments Under GDUFA II

The FDA released final guidance spelling out its review goals for amendments to abbreviated new drug applications and prior approval supplements under GDUFA II.
Source: International Pharmaceutical Regulatory Monitor